Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD157/BST1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD157 ECD-Fc / His Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD157 Products |
| Gene Delivery | CD157 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and conformation-dependent assays. |
View CD157 Products |
| Benchmark Ab | Anti-CD157 Recombinant Antibody Recombinant positive control derived from Clatuzumab (MEN1112) sequence. |
View CD157 Products |
| Validator | CD157 siRNA Set For target knockdown verification and target specificity validation. |
View CD157 Products |
| Related Target A | CD38 Paralogous ectoenzyme. Crucial for counter-screening to prevent off-target toxicity. |
View CD38 Products |
| Related Target B | CD3e T-cell engager partner for bispecific antibody (BsAb) development. |
View CD3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Cynomolgus, and Mouse CD157 ortholog proteins available with >95% purity and verified Theoretical MW. |
| Subfamily counter screening (CD38 cross-reactivity) | Homolog panel proteins (CD38, CD157) strictly verified by mass spectrometry and sequence alignment. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included to establish assay baselines. |
| False Positives in Cell Assays | Validated siRNA sets included for sequence-specific knockdown verification. |
Live CD157/BST1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD157/BST1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting niche indications like acute myeloid leukemia (AML) and epithelial ovarian cancer, where CD157 is highly overexpressed. Overcoming the decoy effect of soluble CD157 (sCD157) shed into the tumor microenvironment remains a primary hurdle for next-generation biologics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (ADCC-enhanced) | Menarini (Clatuzumab / MEN1112) | Acute Myeloid Leukemia (AML) | Epitope mapping & binding kinetics (Need high-purity monomeric ECD) |
| Antibody-Drug Conjugate (ADC) | Preclinical programs | Ovarian Cancer, Mesothelioma | Internalization Assay (Need high-purity ECD-Fc to validate receptor-mediated endocytosis) |
| Bispecific Antibody (BsAb) | Academic & Biotech partnerships | Solid Tumors, Hematological Malignancies | Dual-targeting validation (Need cross-reactive CD157 and CD3e proteins) |
| CAR-T / CAR-NK Cell Therapy | Preclinical developers | Relapsed/Refractory AML | Target cell line validation (Need Lentivirus for stable CD157 overexpression) |